Modern Look at Transverse Myelitis and Inflammatory Myelopathy
Epidemiology of the National Veterans Health Administration Population
Citation Manager Formats
Make Comment
See Comments

Abstract
Background and Objectives To characterize population-level data associated with transverse myelitis (TM) within the US Veterans Health Administration (VHA).
Methods This retrospective review used VHA electronic medical record from 1999 to 2015. We analyzed prevalence, disease characteristics, modified Rankin Scale (mRS) scores, and mortality data in patients with TM based on the 2002 Diagnostic Criteria.
Results We identified 4,084 patients with an International Classification of Diseases (ICD) code consistent with TM and confirmed the diagnosis in 1,001 individuals (90.7% males, median age 64.2, 67.7% Caucasian, and 31.4% smokers). The point prevalence was 7.86 cases per 100,000 people. Less than half of the cohort underwent a lumbar puncture, whereas only 31.8% had a final, disease-associated TM diagnosis. The median mRS score at symptom onset was 3 (interquartile range 2–4), which remained unchanged at follow-up, although less than half (43.2%) of the patients received corticosteroids, IVIg, or plasma exchange. Approximately one-quarter of patients (24.3%) had longitudinal extensive TM, which was associated with poorer outcomes (p = 0.002). A total of 108 patients (10.8%) died during our review (94.4% males, median age 66.5%, and 70.4% Caucasian). Mortality was associated with a higher mRS score at follow-up (OR 1.94, 95% CI, 1.57–2.40) and tobacco use (OR 1.87, 95% CI, 1.17–2.99).
Discussion This national TM review highlights the relatively high prevalence of TM in a modern cohort. It also underscores the importance of a precise and thorough workup in this disabling disorder to ensure diagnostic precision and ensure optimal management for patients with TM in the future.
Glossary
- AQP-4=
- aquaporin-4;
- ICD=
- International Classification of Diseases;
- IQR=
- interquartile range;
- IVIg=
- IV immune globulin;
- LETM=
- longitudinally extensive TM;
- MOG=
- myelin oligodendrocyte;
- mRS=
- modified Rankin Scale;
- MS=
- multiple sclerosis;
- NMOSD=
- neuromyelitis optica spectrum disorder;
- SLE=
- systemic lupus erythematosus;
- TM=
- transverse myelitis;
- TMCWG=
- TM Consortium Working Group;
- VHA=
- Veterans Health Administration;
- VistA=
- VHA Health Information Systems and Technology Architecture
Footnotes
Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.
↵* These authors contributed equally to this work.
The Article Processing Charge was funded by the authors.
- Received April 6, 2021.
- Accepted in final form July 22, 2021.
- Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Predictors of recurrence following an initial episode of transverse myelitisDorlan J. Kimbrough, Maureen A. Mealy, Alexandra Simpson et al.Neurology - Neuroimmunology Neuroinflammation, April 24, 2014 -
Article
Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiologyElia Sechi, Eslam Shosha, Jonathan P. Williams et al.Neurology, June 24, 2019 -
Articles
A population-based study of neuromyelitis optica in CaucasiansN. Asgari, S.T. Lillevang, H.P.B. Skejoe et al.Neurology, May 02, 2011 -
Article
Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritisSudarshini Ramanathan, Stephen W. Reddel, Andrew Henderson et al.Neurology - Neuroimmunology Neuroinflammation, October 29, 2014